Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Spanish Oncology Genito-Urinary Group
Eli Lilly and Company
Altor BioScience
Sanofi
City of Hope Medical Center
GlaxoSmithKline
M.D. Anderson Cancer Center